EP Patent

EP4689660A1 — Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof

Assigned to CTXT Pty Ltd · Expires 2026-02-11 · 0y expired

What this patent protects

This invention relates to a method of selecting a subject having a cancer for treatment, comprising: i) determining a KAT6A level from a biological sample of the cancer from the subject; ii) selecting the subject for treatment and iii) administering to the selected subject an amo…

USPTO Abstract

This invention relates to a method of selecting a subject having a cancer for treatment, comprising: i) determining a KAT6A level from a biological sample of the cancer from the subject; ii) selecting the subject for treatment and iii) administering to the selected subject an amount of with one of: a) a lysine acetyltransferase 6A (KAT6A) inhibitor; b) a lysine acetyltransferase 6A (KAT6A) inhibitor and a cyclin-dependent kinase 4 (CDK4) inhibitor; c) a lysine acetyltransferase 6A (KAT6A) inhibitor and an antiestrogen; and d) a lysine acetyltransferase 6A (KAT6A) inhibitor, a cyclin-dependent kinase 4 (CDK4) inhibitor, and an antiestrogen, based on the KAT6A level, wherein the KAT6A level is determined to be high.

Drugs covered by this patent

Patent Metadata

Patent number
EP4689660A1
Jurisdiction
EP
Classification
—
Expires
2026-02-11
Drug substance claim
No
Drug product claim
No
Assignee
CTXT Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.